

RESEARCH

Open Access



Chronic kidney disease and its health-related factors: a case-control study

Mousa Ghelichi-Ghojogh¹, Mohammad Fararouei^{2*}, Mozhgan Seif³ and Maryam Pakfetrat⁴

Abstract

Background: Chronic kidney disease (CKD) is a non-communicable disease that includes a range of different physiological disorders that are associated with abnormal renal function and progressive decline in glomerular filtration rate (GFR). This study aimed to investigate the associations of several behavioral and health-related factors with CKD in Iranian patients.

Methods: A hospital-based case-control study was conducted on 700 participants (350 cases and 350 controls). Logistic regression was applied to measure the association between the selected factors and CKD.

Results: The mean age of cases and controls were 59.6 ± 12.4 and 58.9 ± 12.2 respectively ($p = 0.827$). The results of multiple logistic regression suggested that many factors including low birth weight ($OR_{yes/no} = 4.07$, 95%CI: 1.76–9.37, $P = 0.001$), history of diabetes ($OR_{yes/no} = 3.57$, 95%CI: 2.36–5.40, $P = 0.001$), history of kidney diseases ($OR_{yes/no} = 3.35$, 95%CI: 2.21–5.00, $P = 0.001$) and history of chemotherapy ($OR_{yes/no} = 2.18$, 95%CI: 1.12–4.23, $P = 0.02$) are associated with the risk of CKD.

Conclusions: The present study covered a large number of potential risk/ preventive factors altogether. The results highlighted the importance of collaborative monitoring of kidney function among patients with the above conditions.

Keywords: Chronic kidney disease, Related factors, Case-control

Background

Chronic kidney disease (CKD) is a non-communicable disease that includes a range of different physiological disorders that are associated with an abnormal renal function and progressive decline in glomerular filtration rate (GFR) [1–3]. Chronic kidney disease includes five stages of kidney damage, from mild kidney dysfunction to complete failure [4]. Generally, a person with stage 3 or 4 of CKD is considered as having moderate to severe kidney damage. Stage 3 is broken up into two levels of kidney damage: 3A) a level of GFR between 45 to 59 ml/min/1.73 m², and 3B) a level of GFR between

30 and 44 ml/min/1.73 m². In addition, GFR for stage 4 is 15–29 ml/min/1.73 m² [4, 5]. It is reported that both the prevalence and burden of CKD are increasing worldwide, especially in developing countries [6]. The worldwide prevalence of CKD (all stages) is estimated to be between 8 to 16%, a figure that may indicate millions of deaths annually [7]. According to a meta-analysis, the prevalence of stage 3 to 5 CKD in South Africa, Senegal, and Congo is about 7.6%. In China, Taiwan, and Mongolia the rate of CKD is about 10.06% and in Japan, South Korea, and Oceania the rate is about 11.73%. In Europe the prevalence of CKD is about 11.86% [8], and finally, about 14.44% in the United States and Canada. The prevalence of CKD is estimated to be about 11.68% among the Iranian adult population and about 2.9% of Iranian women and 1.3% of Iranian men are expected to develop CKD annually [9]. Patients with stages 3 or 4 CKD are at

*Correspondence: fararouei@gmail.com

² HIV/AIDS research center, School of Health, Shiraz University of Medical Sciences, P.O.Box: 71645-111, Shiraz, Iran

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

much higher risk of progressing to either end-stage renal disease (ESRD) or death even prior to the development of ESRD [10, 11].

In general, a large number of risk factors including age, sex, family history of kidney disease, primary kidney disease, urinary tract infections, cardiovascular disease, diabetes mellitus, and nephrotoxins (non-steroidal anti-inflammatory drugs, antibiotics) are known as predisposing and initiating factors of CKD [12–14]. However, the existing studies are suffering from a small sample size of individuals with kidney disease, particularly those with ESRD [15].

Despite the fact that the prevalence of CKD in the world, including Iran, is increasing, the factors associated with CKD are explored very little. The present case-control study aimed to investigate the association of several behavioral and health-related factors with CKD in the Iranian population.

Materials and methods

Settings

In this study, participants were selected among individuals who were registered or were visiting Faghihi and Motahari hospitals (two largest referral centers in the South of Iran located in Shiraz (the capital of Fars province). Cases and controls were frequency-matched by sex and age. The GFR values were calculated using the CKD-EPI formula [16, 17].

Data collection

An interview-administered questionnaire and the participant's medical records were used to obtain the required data. The questionnaire and interview procedure were designed, evaluated, and revised by three experts via conducting a pilot study including 50 cases and 50 controls. The reliability of the questionnaire was measured using the test-retest method (Cronbach's alpha was 0.75). The interview was conducted by a trained public health nurse at the time of visiting the clinics.

Avoiding concurrent conditions that their association may interpreted as reverse causation; the questionnaire was designed to define factors preceding at least a year before experiencing CKD first symptoms. Accordingly participants reported their social and demographic characteristics (age, sex, marital status, educational level, place of residency), history of chronic diseases (diabetes, cardiovascular diseases, hypertension, kidney diseases, family history of kidney diseases, autoimmune diseases and thyroid diseases [18]). Also history of other conditions namely (smoking, urinary tract infection (UTI), surgery due to illness or accident, low birth weight, burns, kidney pain (flank pain), chemotherapy, taking drugs for weight loss or obesity, taking non-steroidal

anti-inflammatory drugs, and taking antibiotic) before their current condition was started. Many researchers reported recalling birth weight to be reliable for research purposes [19]. Moreover, we asked the participants to report their birth weight as a categorical variable (<2500 g or low, 2500–<3500 g or normal, and >3500 g or overweight). Medical records of the participants were used to confirm/complete the reported data. In the case of contradiction between the self-reported and recorded data, we used the recorded information for our study.

Verbal informed consent was obtained from patients because the majority of the participants were illiterate. The study protocol was reviewed and approved by the ethical committee of Shiraz University of Medical Sciences (approval number: 1399.865).

Sample size

The sample size was calculated to detect an association between the history of using antibiotics (one of our main study variables) and CKD as small as $OR = 1.5$ [20]. With an alpha value of 0.05 (2-sided) and a power of 80%, the required sample size was estimated as large as $n = 312$ participants for each group.

Selection of cases

The selected clinics deliver medical care to patients from the southern part of the country. In this study, patients with CKD who were registered with the above centers from June to December 2020 were studied. A case was a patient with a $GFR < 60$ (ml/min/1.73 m²) at least twice in 3 months. According to the latest version of the International Classification of Diseases (2010), Codes N18.3 and N18.4 are assigned to patients who have ($GFR = 30–59$ (ml/min/1.73 m²) and $GFR = 15–29$ (ml/min/1.73 m²) respectively [21]. In total, 350 patients who were diagnosed with CKD by a nephrologist during the study period.

Selection of the controls

We used hospital controls to avoid recall-bias. The control participants were selected from patients who were admitted to the general surgery (due to hernia, appendicitis, intestinal obstruction, hemorrhoids, and varicose veins), and orthopedic wards from June to December 2020. Using the level of creatinine in the participants' serum samples, GFR was calculated and the individuals with normal GFR (ml/min/1.73 m²) $GFR > 60$) and those who reported no history of CKD were included ($n = 350$).

Inclusion criteria

Patients were included if they were ≥ 20 years old and had a definitive diagnosis of CKD by a nephrologist.

Exclusion criteria

Participants were excluded if they were critically ill, had acute kidney injury, those undergone renal transplantation, and those with cognitive impairment.

Statistical analysis

The Chi-square test was used to measure the unadjusted associations between categorical variables and CKD. Multiple logistic regression was applied to measure the adjusted associations for the study variables and CKD. The backward variable selection strategy was used to include variables in the regression model. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. All *p*-values were two-sided and the results were considered statistically significant at *p* < 0.05. All analyses were conducted using Stata version 14.0 (Stata Corporation, College Station, TX, USA).

Results

In total, 350 cases and 350 age and sex-matched controls were included in the analysis. The mean age of cases and controls were 59.6 ± 12.4 and 58.9 ± 12.2 respectively (*p* = 0.83). Overall, 208 patients (59.4%) and 200 controls (57.1%) were male (*p* = 0.54). Also, 149 patients (42.6%) and 133 controls (38.0%) were illiterate or had elementary education (*p* = 0.001). Most cases (96.9%) and controls (95.7%) were married (*p* = 0.42). The mean GFR for CKD and control groups were 38.6 ± 11.4 and 78.3 ± 10.2 (ml/min/1.73 m²) respectively.

Result of univariate analysis

Table 1 illustrates the unadjusted associations of demographic and health-related variables with CKD. Accordingly, significant (unadjusted) associations were found between the risk of CKD and several study variables including education, history of chronic diseases (diabetes, cardiovascular, hypertension, kidney diseases, autoimmune diseases, and hypothyroidism), family history of kidney diseases, smoking, UTI, surgery due to illness or accident, low birth weight, burns, kidney pain, chemotherapy, taking non-steroidal anti-inflammatory drugs, and taking antibiotics (*P* < 0.05 for all).

Results of multivariable analysis

Table 2 illustrates the adjusted associations between the study variables and the risk of CKD. Most noticeably, low birth weight (OR_{yes/no} = 4.07, 95%CI: 1.76–9.37, *P* = 0.001), history of surgery (OR_{yes/no} = 1.74, 95%CI: 1.18–2.54, *P* = 0.004), family history of kidney diseases (OR_{yes/no} = 1.97, 95%CI: 1.20–3.23, *P* = 0.007), and history of chemotherapy (OR_{yes/no} = 2.18, 95%CI:

Table 1 Unadjusted associations between demographic and health related variables with the risk of CKD

Variables	Cases (N = 350) n (%)	Controls (N = 350) n (%)	P-value*
Sex			
Female	142 (40.6)	150 (42.9)	0.54
Male	208 (59.4)	200 (57.1)	
Age group			
20- < 40	30 (8.6)	32 (9.1)	0.989
40- < 50	49 (14.0)	50 (14.3)	
50- < 60	89 (25.4)	90 (25.7)	
≥ 60	182 (52.0)	178 (50.9)	
Place of residency			
Rural	93 (26.6)	103 (29.4)	0.412
Urban	257 (73.4)	247 (70.6)	
Education			
Illiterate or elementary	149 (42.6)	133 (38.0)	0.001
Middle school	86 (24.6)	68 (19.4)	
High school	68 (19.4)	60 (17.1)	
College	47 (13.4)	89 (25.4)	
Marriage status			
Single	11 (3.1)	15 (4.3)	0.424
Married	399 (96.9)	335 (95.7)	
Job			
Employed	74 (21.1)	64 (18.3)	0.154
Unemployed	174 (49.7)	160 (45.7)	
Household	102 (29.1)	126 (36)	
History of diabetes			
No	181 (51.7)	292 (83.4)	0.001
Yes	169 (48.3)	58 (16.6)	
History of HTN**			
No	119 (34.0)	248 (70.9)	0.001
Yes	231 (66.0)	102 (29.1)	
History of cardiovascular diseases			
No	212 (60.6)	290 (82.9)	< 0.001
Yes	138 (39.4)	60 (17.1)	
History of kidney diseases			
No	170 (48.6)	279 (79.7)	0.001
Yes	180 (51.4)	71 (20.3)	
Family history of kidney diseases			
No	250 (71.43)	305 (87.1)	0.001
Yes	100 (28.57)	45 (12.9)	
History of smoking			
No	207 (59.1)	233 (66.6)	0.003
Yes	143 (40.9)	117 (33.4)	
Autoimmune diseases			
No	319 (91.1)	335 (95.7)	0.015
Yes	31 (8.9)	15 (4.3)	
Hypothyroidism			
No	298 (85.1)	318 (90.9)	0.02
Yes	52 (14.9)	32 (9.1)	

Table 1 (continued)

Variables	Cases (N = 350) n (%)	Controls (N = 350) n (%)	P-value*
History of UTI***			
No	232 (66.3)	288 (82.3)	< 0.001
Yes	118 (33.7)	62 (17.7)	
History of surgery due to illness or accident			
No	123 (35.1)	193 (55.1)	0.001
Yes	227 (64.9)	157 (44.9)	
Low birth weight			
No	316 (90.3)	338 (96.6)	0.001
Yes	34 (9.7)	12 (3.4)	
History of burns			
No	309 (88.3)	334 (95.4)	< 0.001
Yes	41 (11.7)	16 (4.6)	
History of kidney pain			
Not at all	192 (54.9)	231 (66.0)	< 0.001
Seldom	39 (11.1)	51 (14.6)	
Sometimes	62 (17.7)	45 (12.9)	
Mostly	57 (16.3)	23 (6.6)	
History of chemotherapy			
No	309 (88.5)	327 (93.4)	0.024
Yes	40 (11.5)	23 (6.6)	
History of taking drugs for weight loss			
No	326 (93.1)	336 (96.0)	0.095
Yes	24 (6.9)	14 (4.0)	
History of taking non-steroidal anti-inflammatory drugs			
No	203 (58.0)	254 (72.6)	0.001
Yes	147 (42.0)	96 (27.4)	
History of taking antibiotic			
Never	55 (15.7)	63 (18.0)	0.001
Rarely	154 (44.0)	222 (63.4)	
Sometime	100 (28.6)	57 (16.3)	
Frequently	41 (11.7)	8 (2.3)	

*Chi-square test; **HTN Hypertension; ***UTI Urinary tract infection

1.12–4.23, $P = 0.02$) were significantly associated with a higher risk of CKD. On the other hand, education (OR college/illiterate or primary = 0.54, 95%CI: 0.31–0.92, $P = 0.025$) was found to be inversely associated with CKD.

Discussion

The results of the present study suggested that several variables including, education, history of diabetes, history of hypertension, history of kidney diseases or a family history of kidney diseases, history of surgery due to illness or accident, low birth weight, history of chemotherapy, history of taking non-steroidal anti-inflammatory drugs, and history of taking antibiotics may affect the risk of CKD.

Table 2 Adjusted association between the study variables and risk of CKD

Variables ^a	OR ^b	95% CI ^c	P-value
Education			
Illiterate or elementary	1	–	–
Middle school	1.41	0.85–2.31	0.174
High school	1.41	0.85–2.31	0.002
College	0.54	0.31–0.92	0.025
History of diabetes			
No	1	–	–
Yes	3.57	2.36–5.40	0.001
History of hypertension			
No	1	–	–
Yes	2.88	1.95–4.25	0.001
History of kidney diseases			
No	1	–	–
Yes	3.35	2.21–5.0	0.001
Family history of kidney diseases			
No	1	–	–
Yes	1.97	1.20–3.23	0.007
History of surgery			
No	1	–	–
Yes	1.74	1.18–2.54	0.004
low birth weight			
No	1	–	–
Yes	4.07	1.76–9.37	0.001
History of chemotherapy			
No	1	–	–
Yes	2.18	1.12–4.23	0.02
History of taking non-steroidal anti-inflammatory drugs			
No	1	–	–
Yes	1.66	1.12–2.47	0.012
History of taking antibiotic			
Never	1	–	–
Rarely	0.76	0.46–1.26	0.296
Sometime	2.03	1.13–3.36	0.018
Frequently	5.55	2.10–14.69	0.001

^aThe full model included education, history of chronic diseases (diabetes, cardiovascular, hypertension, kidney diseases, autoimmune diseases and hypothyroidism), family history of kidney diseases, smoking, UTI, surgery due to illness or accident, low birth weight, burns, kidney pain, chemotherapy, taking non-steroidal anti-inflammatory drugs, and taking antibiotics); ^bOR odds ratio; ^cCI confidence interval

In our study, the level of education was inversely associated with the risk of CKD. This finding is in accordance with the results of a study conducted by K Lambert et.al, who suggested that illiteracy or elementary education may raise the risk of CKD [22]. The fact that education level is associated with health literacy, may partly explain our results that lower education and inadequate health literacy in individuals with CKD is associated with worse

health outcomes including poorer control of biochemical parameters, higher risk of cardiovascular diseases (CVDs); a higher rate of hospitalization, and a higher rate of infections [23].

In the current study, the history of diabetes was associated with a higher risk of CKD. This finding is consistent with the results of other studies on the same subject [20, 21, 24–27]. It is not surprising that people with diabetes have an increased risk of CKD as diabetes is an important detrimental factor for kidney functioning as approximately, 40% of patients with diabetes develop CKD [27].

The other variable that was associated with an increased risk of CKD was a history of hypertension. Our result is consistent with the results of several other studies [20, 24, 25, 28]. It is reported that hypertension is both a cause and effect of CKD and accelerates the progression of the CKD to ESRD [29].

After controlling for other variables, a significant association was observed between family history of kidney diseases and risk of CKD. Published studies suggested the same pattern [24]. Inherited kidney diseases (IKDs) are considered as the foremost reasons for the initiation of CKD and are accounted for about 10–15% of kidney replacement therapies (KRT) in adults [30].

The importance of the history of surgery due to illness or accident in this study is rarely investigated by other researchers who reported the effect of surgery in patients with acute kidney injury (AKI), and major abdominal and cardiac surgeries [31, 32] on the risk of CKD. Also, AKI is associated with an increased risk of CKD with progression in various clinical settings [33–35]. In a study by Mizota et.al, although most AKI cases recovered completely within 7 days after major abdominal surgery, they were at higher risk of 1-year mortality and chronic kidney disease compared to those without AKI [31].

The present study also showed that low birth weight is a significant risk factor for CKD. This finding is consistent with the results of some other studies. However, the results of very few studies on the association between birth weight and risk of CKD are controversial as some suggested a significant association [19, 36, 37] whereas others suggested otherwise [36]. This may be explained by the relatively smaller size and volume of kidneys in LBW infants compared to infants that are normally grown [38]. This can lead to long-term complications in adolescence and adulthood including hypertension, decreased glomerular filtration, albuminuria, and cardiovascular diseases. Eventually, these long-term complications can also cause CKD [39].

Another important result of the current study is the association between chemotherapy for treating cancers and the risk of CKD. According to a study on chemotherapy for testicular cancer by Inai et al., 1 year after

chemotherapy 23% of the patients showed CKD [40]. Another study suggested that the prevalence of stage 3 CKD among patients with cancer was 12, and <1% of patients had stage 4 CKD [41, 42]. Other studies have shown an even higher prevalence of CKD among cancer patients. For instance, only 38.6% of patients with breast cancer, 38.9% of patients with lung cancer, 38.3% of patients with prostate cancer, 27.5% of patients with gynecologic cancer, and 27.2% of patients with colorectal cancer had a $GFR \geq 90$ (ml/min/1.73 m²) at the time of therapy initiation [43, 44]. The overall prevalence of CKD ranges from 12 to 25% across many cancer patients [45–47]. These results clearly demonstrate that, when patients with cancer develop acute or chronic kidney disease, outcomes are inferior, and the promise of curative therapeutic regimens is lessened.

In our study, the history of taking nephrotoxic agents (antibiotics or NSAIDs drugs) was associated with a higher risk of CKD. Our result is following the results reported by other studies [48, 49]. Common agents that are associated with AKI include NSAIDs are different drugs including antibiotics, iodinated contrast media, and chemotherapeutic drugs [50].

Strengths and limitations of our study

Our study used a reasonably large sample size. In addition, a considerably large number of study variables was included in the study. With a very high participation rate, trained nurses conducted the interviews with the case and control participants in the same setting. However, histories of exposures are prone to recall error (bias), a common issue in the case-control studies. It is to be mentioned that the method of selecting controls (hospital controls) should have reduced the risk of recall bias when reporting the required information. In addition, we used the participants' medical records to complete/ confirm the reported data. Although the design of the present study was not able to confirm a causal association between the associated variables and CKD, the potential importance and modifiable nature of the associated factors makes the results potentially valuable and easily applicable in the prevention of CKD.

Conclusions

Given that, chemotherapy is an important risk factor for CKD, we suggest the imperative for collaborative care between oncologists and nephrologists in the early diagnosis and treatment of kidney diseases in patients with cancer. Training clinicians and patients are important to reduce the risk of nephrotoxicity. Electronic medical records can simultaneously be used to monitor prescription practices, responsiveness to alerts and prompts, the incidence of CKD, and detecting barriers

to the effective implementation of preventive measures [51]. Routine follow-up and management of diabetic patients is also important for the prevention of CKD. We suggest a tight collaboration between endocrinologists and nephrologists to take care of diabetic patients with kidney problems. In addition, surgeons in major operations should refer patients, especially patients with AKI, to a nephrologist for proper care related to their kidney function. Treatment of hypertension is among the most important interventions to slow down the progression of CKD [12]. Moreover, all patients with newly diagnosed hypertension should be screened for CKD. We suggest all patients with diabetes have their GFR and urine albumin-to-creatinine ratio (UACR) checked annually. Finally, the aging population and obesity cause the absolute numbers of people with diabetes and kidney diseases to raise significantly. This will require a more integrated approach between diabetologists/nephrologists and the primary care teams (55).

Abbreviations

CKD: Chronic kidney disease; ESRD: End-stage renal disease; GFR: Glomerular filtration rate; RRT: Renal replacement treatment; UTI: Urinary tract infection; OR: Odds ratios; CI: Confidence intervals; HTN: Hypertension; AKI: Acute kidney injury.

Acknowledgments

This paper is part of a thesis conducted by Mousa Ghelichi-Ghojogh, Ph.D. student of epidemiology, and a research project conducted at the Shiraz University of Medical sciences (99-01-04-22719). We would like to thank Dr. Bahram Shahryari and all nephrologists of Shiraz University of medical sciences, interviewers, and CKD patients in Shiraz for their voluntary participation in the study and for providing data for the study.

Authors' contributions

MGG: Conceptualization, Methodology, Statistical analysis, Investigation, and writing the draft of the manuscript. MP: were involved in methodology, writing the draft of the manuscript, and clinical consultation. MS: was involved in the methodology and statistical analysis. MF: was involved in conceptualization, methodology, supervision, writing, and reviewing the manuscript. The authors read and approved the final manuscript.

Funding

Shiraz University of Medical Sciences financially supported this study. (Grant number: 99-01-04-22719).

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to their being the intellectual property of Shiraz University of Medical Sciences but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study protocol was reviewed and approved by the ethical committee of Shiraz University of Medical Sciences (approval number: 1399.865). All methods were performed in accordance with the relevant guidelines and regulations of the Declaration of Helsinki. The participants were assured that their information is used for research purposes only. Because of the illiteracy of a considerable number of the patients, verbal informed consent was obtained

from the participants. Using verbal informed consent was also granted by the ethical committee of Shiraz University of Medical Sciences.

Consent for publication

Not applicable.

Competing interests

None of the authors declare disclosures of direct relevance to the submitted work.

Author details

¹Candidate in Epidemiology, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. ²HIV/AIDS research center, School of Health, Shiraz University of Medical Sciences, P.O.Box: 71645-111, Shiraz, Iran. ³Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran. ⁴Nephrologist, Shiraz Nephro-Urology Research Center, Department of Internal Medicine, Emergency Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: 14 August 2021 Accepted: 24 December 2021

Published online: 10 January 2022

References

- Ghelichi Ghojogh M, Salarilak S, Taghezadeh Afshari A, Khalkhali HR, Mohammadi-Fallah MR, Mkhdoomi K. The effect of body mass index on patient and graft survival rate in kidney transplanted patients in Iran. *Nephrourol Monthly*. 2017;9(4):e14386.
- Zeba Z, Fatema K, Sumit AF, Zinnat R, Ali L. Early screening of chronic kidney disease patients among the asymptomatic adult population in Bangladesh. *J Prev Epidemiol*. 2020;5(1):e10–e.
- Mahajan C, Tiwari V, Divyaveer SS, Patil MR, Banerjee A, Bagur V, et al. Spectrum of renal biopsies; a three-year data from a tertiary care Centre of eastern India. *J Nephropharmacol*. 2020;9(2):e20–e.
- Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic Hyperuricemia: a randomized trial. *Am J Kidney Dis*. 2018;72(6):798–810.
- Foster MC, Hwang S-J, Larson MG, Lichtman JH, Parikh NI, Vasan RS, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham heart study. *Am J Kidney Dis*. 2008;52(1):39–48.
- Rachmi CN, Agho KE, Li M, Baur LA. Stunting, underweight and overweight in children aged 2.0–4.9 years in Indonesia: prevalence trends and associated risk factors. *PLoS One*. 2016;11(5):e0154756.
- Asghari G, Momenan M, Yuzbashian E, Mirmiran P, Azizi F. Dietary pattern and incidence of chronic kidney disease among adults: a population-based study. *Nutr Metab*. 2018;15(1):1–11.
- Ruggles DR, Freyman RL, Oxenham AJ. Influence of musical training on understanding voiced and whispered speech in noise. *PLoS One*. 2014;9(1):e86980.
- Moazzeni SS, Arani RH, Hashemini M, Tohidi M, Azizi F, Hadaegh F. High incidence of chronic kidney disease among Iranian diabetic adults: using CKD-EPI and MDRD equations for estimated glomerular filtration rate. *Korean Diabetes J*. 2021;45(5):684–97.
- Salam SN, Eastell R, Khwaja A. Fragility fractures and osteoporosis in CKD: pathophysiology and diagnostic methods. *Am J Kidney Dis*. 2014;63(6):1049–59.
- Zahmatkesh M, Tamadon MR. World kidney day 2018; chronic kidney disease in women. *J Nephropathol*. 2017;7(1):4–6.
- Noble R, Taal MW. Epidemiology and causes of chronic kidney disease. *Medicine*. 2019;47(9):562–6.
- Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. *Am J Clin Nutr*. 2004;80(4):1029–35.
- Sepahi MA, Niknafs B. Multifaceted role of apolipoprotein L1 risk variants and nephropathy. *J Nephropathol*. 2020;9(1):1–3.
- Cohen JB, Tewksbury CM, Landa ST, Williams NN, Dumon KR. National postoperative bariatric surgery outcomes in patients with chronic kidney disease and end-stage kidney disease. *Obes Surg*. 2019;29(3):975–82.

16. Levey AS, Andreoli SP, DuBoise T, Provenzano R, Collins AJ. Chronic kidney disease: common, harmful and treatable—world kidney day 2007. *Am J Nephrol*. 2007;27(1):108–12.
17. Argulian E, Sherid MV, Messerli FH. Misconceptions and facts about hypertrophic cardiomyopathy. *Am J Med*. 2016;129(2):148–52.
18. Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. *Curr Opin Endocrinol Diabetes Obes*. 2016;23(5):407.
19. Al Salmi I, Hoy WE, Kondalsamy-Chennakes S, Wang Z, Healy H, Shaw JE. Birth weight and stages of CKD: a case-control study in an Australian population. *Am J Kidney Dis*. 2008;52(6):1070–8.
20. Yacoub R, Habib H, Lahdo A, Al Ali R, Varjabedian L, Atalla G, et al. Association between smoking and chronic kidney disease: a case control study. *BMC Public Health*. 2010;10(1):1–6.
21. Saucier NA, Sinha MK, Liang KV, Krambeck AE, Weaver AL, Bergstralh EJ, et al. Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. *Am J Kidney Dis*. 2010;55(1):61–8.
22. Lambert K, Mullan J, Mansfield K, Loneragan M. A cross-sectional comparison of health literacy deficits among patients with chronic kidney disease. *J Health Commun*. 2015;20(sup2):16–23.
23. Fraser SD, Roderick PJ, Casey M, Taal MW, Yuen HM, Nutbeam D. Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. *Nephrol Dial Transplant*. 2013;28(1):129–37.
24. Ji MY, Park YS, Yi SE. A case-control study to identify the risk factors of school accidents. *Korean J Epidemiol*. 2005;27(2):80–94.
25. Khajehdehi P, Malekmakan L, Pakfetrat M, Roozbeh J, Sayadi M. Prevalence of chronic kidney disease and its contributing risk factors in southern Iran: a cross-sectional adult population-based study; 2014.
26. Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from global burden of disease 2017. *J Diabetes Investig*. 2021;12(3):346.
27. Xu Y, Surapaneni A, Alkas J, Evans M, Shin J-I, Selvin E, et al. Glycemic control and the risk of acute kidney injury in patients with type 2 diabetes and chronic kidney disease: parallel population-based cohort studies in US and Swedish routine care. *Diabetes Care*. 2020;43(12):2975–82.
28. Sepanlou SG, Barahimi H, Najafi I, Kamangar F, Poustchi H, Shakeri R, et al. Prevalence and determinants of chronic kidney disease in northeast of Iran: results of the Golestan cohort study. *PLoS One*. 2017;12(5):e0176540.
29. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. *Drugs*. 2019;79(4):365–79.
30. Torra R, Furlano M, Ortiz A, Ars E. Genetic kidney diseases as an under-recognized cause of chronic kidney disease: the key role of international registry reports. *Clin Kidney J*. 2021;14(8):1879–85.
31. Mizota T, Dong L, Takeda C, Shiraki A, Matsukawa S, Shimizu S, et al. Transient acute kidney injury after major abdominal surgery increases chronic kidney disease risk and 1-year mortality. *J Crit Care*. 2019;50:17–22.
32. Madsen NL, Goldstein SL, Frøslev T, Christiansen CF, Olsen M. Cardiac surgery in patients with congenital heart disease is associated with acute kidney injury and the risk of chronic kidney disease. *Kidney Int*. 2017;92(3):751–6.
33. Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. *Arch Intern Med*. 2008;168(6):609–16.
34. Ishani A, Nelson D, Clothier B, Schult T, Nugent S, Greer N, et al. The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. *Arch Intern Med*. 2011;171(3):226–33.
35. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. *Circulation*. 2011;123(4):409–16.
36. Esmeijer K, de Vries AP, Mook-Kanamori DO, de Fijter JW, Rosendaal FR, Rabelink TJ, et al. Low birth weight and kidney function in middle-aged men and women: the Netherlands epidemiology of obesity study. *Am J Kidney Dis*. 2019;74(6):751–60.
37. White SL, Perkovic V, Cass A, Chang CL, Poulter NR, Spector T, et al. Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. *Am J Kidney Dis*. 2009;54(2):248–61.
38. Harer MW, Charlton JR, Tipple TE, Reidy KJ. Preterm birth and neonatal acute kidney injury: implications on adolescent and adult outcomes. *J Perinatol*. 2020;40(9):1286–95.
39. Al Salmi I, Hannawi S. Birth weight and susceptibility to chronic kidney disease. *Saudi J Kidney Dis Transplant*. 2020;31(4):717.
40. Inai H, Kawai K, Ikeda A, Ando S, Kimura T, Oikawa T, et al. Risk factors for chronic kidney disease after chemotherapy for testicular cancer. *Int J Urol*. 2013;20(7):716–22.
41. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. *Cancer*. 2007;110(6):1376–84.
42. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. *Semin Nephrol*. 2010;30(6):548–56.
43. Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. *ESMO Open*. 2016;1(4):e000091.
44. Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. *Br J Cancer*. 2010;103(12):1815–21.
45. Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, et al. Acute kidney injury in patients receiving systemic treatment for Cancer: a population-based cohort study. *J Natl Cancer Inst*. 2019;111(7):727–36.
46. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for acute kidney injury. kdigo.org/wpcontent/uploads/2016/10/KDIGO-2012-AKI-Guide-line-Engli-sh.pdf. Accessed 23 Mar 2020.
47. Königsbrügge O, Lötsch F, Zielinski C, Pabinger I, Ay C. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. *Thromb Res*. 2014;134(1):44–9.
48. Goldstein SL, Mottes T, Simpson K, Barclay C, Muething S, Haslam DB, et al. A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. *Kidney Int*. 2016;90(1):212–21.
49. Menon S, Kirkendall ES, Nguyen H, Goldstein SL. Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6 months. *J Pediatr*. 2014;165(3):522–7.e2.
50. Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. *Kidney Int*. 2015;87(5):909–17.
51. Luyckx VA, Tuttle KR, Garcia-Garcia G, Gharbi MB, Heerspink HJL, Johnson DW, et al. Reducing major risk factors for chronic kidney disease. *Kidney Int Suppl*. 2017;7(2):71–87.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

